Blood Res.  2016 Mar;51(1):58-61. 10.5045/br.2016.51.1.58.

Comparison of an international scale method and a log reduction method for monitoring of early molecular response in chronic myeloid leukemia patients

• Ahn S
• Lim YA
• Lee WG
• Jeong SH
• Park JS
• Cho SR

• KMID: 2172746
• DOI: http://doi.org/10.5045/br.2016.51.1.58

Abstract

No abstract available.

MeSH Terms

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

Figure

• 

  Fig. 1 Correlation between the international scale (IS) values and the log10 reductions in BCR-ABL1 levels in the chronic myeloid leukemia patients at 3 months after imatinib mesylate therapy. Abscissa indicates IS values obtained by the BCR-ABL Mbcr IS-MMR Dx kit. Ordinate indicates the log10 reductions in BCR-ABL1 levels from baseline obtained by the LightCycler t(9;22) quantification kit.

Reference

1. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349:1423–1432. PMID: 14534335.

2. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112:3330–3338. PMID: 18684859.

3. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108:28–37. PMID: 16522812.

4. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27:6041–6051. PMID: 19884523.

5. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30:232–238. PMID: 22067393.

6. Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26:2096–2102. PMID: 22446502.

7. Park JS, Yi JW, Jeong SH, et al. Comparison of multiplex reverse transcription polymerase chain reaction and conventional cytogenetics as a diagnostic strategy for acute leukemia. Int J Lab Hematol. 2008; 30:513–518. PMID: 18983303.

8. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003; 17:2318–2357. PMID: 14562125.

9. Beillard E, Pallisgaard N, van der, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003; 17:2474–2486. PMID: 14562124.

10. Quintás-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009; 113:6315–6321. PMID: 19369233.

11. Qin YZ, Jiang Q, Jiang H, et al. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level? Leuk Res. 2013; 37:1035–1040. PMID: 23810191.

12. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355:2408–2417. PMID: 17151364.

13. Fava C, Kantarjian H, Cortes J. Molecular resistance: an early indicator for treatment change? Clin Lymphoma Myeloma Leuk. 2012; 12:79–87. PMID: 22285607.

14. Stanoszek LM, Crawford EL, Blomquist TM, Warns JA, Willey PF, Willey JC. Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples. J Mol Diagn. 2013; 15:391–400. PMID: 23541592.

15. Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26:2172–2175. PMID: 22504141.